Ovid Therapeutics (OVID) to Release Earnings on Tuesday

Ovid Therapeutics (NASDAQ:OVID) is expected to be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Ovid Therapeutics to post earnings of ($0.12) per share and revenue of $0.0570 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Wednesday, March 18th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.16. Ovid Therapeutics had a negative net margin of 240.11% and a negative return on equity of 23.98%. The business had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $0.06 million. On average, analysts expect Ovid Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ovid Therapeutics Stock Down 0.5%

Shares of Ovid Therapeutics stock traded down $0.02 on Tuesday, hitting $2.92. 1,081,915 shares of the company traded hands, compared to its average volume of 2,638,891. The company has a quick ratio of 8.97, a current ratio of 8.97 and a debt-to-equity ratio of 0.09. The company has a market cap of $384.42 million, a PE ratio of -9.40 and a beta of 0.18. The company has a 50-day moving average price of $2.29 and a 200 day moving average price of $1.81. Ovid Therapeutics has a 12-month low of $0.27 and a 12-month high of $3.11.

Wall Street Analyst Weigh In

OVID has been the subject of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $4.00 price objective on shares of Ovid Therapeutics in a report on Thursday, March 26th. Wall Street Zen upgraded shares of Ovid Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. HC Wainwright increased their target price on shares of Ovid Therapeutics from $2.00 to $4.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of Ovid Therapeutics in a research note on Wednesday, April 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Ovid Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $4.63.

Institutional Trading of Ovid Therapeutics

Several hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. bought a new stake in shares of Ovid Therapeutics during the fourth quarter valued at approximately $17,464,000. Affinity Asset Advisors LLC boosted its position in shares of Ovid Therapeutics by 169.8% during the fourth quarter. Affinity Asset Advisors LLC now owns 7,150,000 shares of the company’s stock worth $11,654,000 after purchasing an additional 4,500,000 shares in the last quarter. ADAR1 Capital Management LLC boosted its position in shares of Ovid Therapeutics by 33,256.7% during the fourth quarter. ADAR1 Capital Management LLC now owns 4,285,000 shares of the company’s stock worth $6,985,000 after purchasing an additional 4,272,154 shares in the last quarter. Federated Hermes Inc. bought a new position in shares of Ovid Therapeutics during the fourth quarter worth $5,307,000. Finally, Adage Capital Partners GP L.L.C. boosted its position in shares of Ovid Therapeutics by 158.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,492,000 shares of the company’s stock worth $5,692,000 after purchasing an additional 2,142,000 shares in the last quarter. 72.24% of the stock is owned by institutional investors.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.